{"article_id": "WAT_q3_2020.txt", "article": ["after steep declines in the second quarter , third quarter sales were up 2 % year - over - year on a constant currency basis and adjusted earnings per share grew 1 % .", "first , from a customer perspective , our largest segment , pharma , was the primary growth driver in the quarter with 4 % organic growth , followed by industrial , which grew 3 % and academic and government , which declined 7 % .", "from a product perspective , our waters branded products and services grew 3 % organically , while ta declined by 8 % on a constant currency basis .", "services grew 4 % , while consumables business grew approximately 7 % organically , driven largely by pharma .", "moreover , our strong base of small molecules , which represents approximately 75 % to 80 % of pharmaceutical industry sales will benefit from the growth of cros , oligonucleotides and mrna therapeutics , as well as the increasing potential for repatriation of small molecule manufacturing .", "we have a global footprint with 25 % of our sales coming from china and india .", "for example , there are thousands of alliance systems in service that are more than 20 years old and in need of an upgrade .", "second , approximately 20 % of our consumable sales go through the e-commerce channel .", "for many of our competitors , this number is over 50 % .", "in the third quarter , we recorded net sales of $ 594 million , an increase of approximately 2 % in constant currency .", "currency translation increased sales growth by approximately 1 % , resulting in sales growth of 3 % , as reported .", "in the quarter , sales into our pharmaceutical market increased 4 % , sales into our industrial market increased 3 % , while academic and governmental markets declined 7 % .", "looking at our product line growth , our recurring revenue , which represents the combination of precision chemistry products and service revenue , increased by 5 % in the quarter , but instrument sales declined 1 % .", "industry revenues were up 7 % in the third quarter , driven by strong pharma market growth .", "on the service side of our business , revenues were up 4 % as on - demand service bounced back to mid-single digit growth along with continued growth in service plan revenues within the waters product line , bringing third quarter product sales down further .", "sales related to waters branded products and services grew 3 % , while sales of ta branded products and services declined 8 % .", "combined lc instrument platform sales and lc - ms instrument platform sales were flat and ta 's instrumentation system sales declined 10 % .", "looking at our growth rates in the third quarter geographically and on a constant currency basis , sales in asia were flat with china up 3 % , sales in americas grew 2 % with u.s. growing 5 % , and european sales grew 5 % .", "we are on - track to achieve cost savings of approximately $ 100 million for the year relative to our pre-covid internal plan .", "we achieved approximately 25 % of our planned annual savings in the third quarter , bringing our year - to - date savings against our internal plan to 85 % , with the majority recognized in the second quarter .", "we expect to realize remaining 15 % in the fourth quarter .", "returning to our third quarter non-gaap financial performance , gross margin for the quarter was 55.8 % compared to 58.2 % in the third quarter of 2019 , primarily as a result of unfavorable fx as well as fixed cost absorption and sales mix .", "moving down the third quarter p&l , operating expenses increased by approximately 1 % on a constant currency basis and foreign currency translation increased operating expense growth by approximately 2 % on a reported basis .", "in the quarter , our effective operating tax rate was 15.8 % , which was about flat for the prior year .", "net interest expense was $ 7 million , a decrease of about $ 1 million .", "our average share count came in at 62.3 million shares , a share count reduction of approximately 7 % or about 4 million shares lower than in the third quarter of last year as a result of shares repurchased through the end of the first quarter of 2020 , subsequent to which we paused the share repurchase program .", "our non-gaap earnings per fully diluted share for the third quarter increased to $ 2.16 in comparison to $ 2.13 last year .", "on a gaap basis , our earnings per fully diluted share decreased to $ 2.03 compared to $ 2.07 last year .", "in the third quarter of 2020 , free cash flow grew 53 % year - over - year to $ 190 million , after funding $ 28 million of capital expenditures .", "excluded from free cash flow was $ 7 million related to the investment in our taunton precision chemistry operation and a $ 38 million transition tax payment related to 2017 u.s. tax reform .", "in the third quarter , this resulted in $ 0.32 of each dollar of sales converted into free cash flow and $ 0.31 year - to - date .", "accounts receivable days sales outstanding came in at 76 days this quarter , down four days compared to the third quarter of last year and down 11 days from the second quarter .", "inventories decreased by $ 42 million in comparison to the prior year quarter , reflecting stronger revenue growth and revised production schedules .", "we ended the quarter with cash and short - term investments of $ 397 million and debt of $ 1.6 billion on our balance sheet at the end of the quarter .", "this resulted in a net debt position of $ 1.2 billion and a net debt - to - ebitda ratio of about 1.6 times at the end of the third quarter .", "we also have $ 1.2 billion available on our bank revolver for total available liquidity of $ 1.6 billion at the end of third quarter .", "our future capital structure target of approximately 2.5 times net debt - to - ebitda remains unchanged , while our near - term focus is maintaining financial flexibility and variability in the macro environment .", "we now expect full year operating expenses to be in the range of down 1 % to flat year - over - year in constant currency .", "for the full year , at current rates , currency translation is expected to be about neutral to sales growth to positively impact operating expense growth by less than 1 percentage point and to negatively impact earnings per share by about 3 percentage points .", "for the full year , net interest expense is expected to be in the range of $ 38 million to $ 40 million primarily due to lower debt levels ."], "summary_gold": "compname reports q3 non -gaap earnings per share $ 2.16 .<q>q3 non -gaap earnings per share $ 2.16 .<q>q3 gaap earnings per share $ 2.03 .<q>q3 sales $ 594 million versus refinitiv ibes estimate of $ 546.5 million .", "summary_pred": "industry revenues were up 7 % in the third quarter , driven by strong pharma market growth .<q>we have a global footprint with 25 % of our sales coming from china and india .<q>moreover , our strong base of small molecules , which represents approximately 75 % to 80 % of pharmaceutical industry sales will benefit from the growth of cros , oligonucleotides and mrna therapeutics , as well as the increasing potential for repatriation of small molecule manufacturing .<q>for example , there are thousands of alliance systems in service that are more than 20 years old and in need of an upgrade .<q>currency translation increased sales growth by approximately 1 % , resulting in sales growth of 3 % , as reported .<q>excluded from free cash flow was $ 7 million related to the investment in our taunton precision chemistry operation and a $ 38 million transition tax payment related to 2017 u.s. tax reform .<q>from a product perspective , our waters branded products and services grew 3 % organically , while ta declined by 8 % on a constant currency basis .<q>we are on - track to achieve cost savings of approximately $ 100 million for the year relative to our pre-covid internal plan .<q>we ended the quarter with cash and short - term investments of $ 397 million and debt of $ 1.6 billion on our balance sheet at the end of the quarter .<q>inventories decreased by $ 42 million in comparison to the prior year quarter , reflecting stronger revenue growth and revised production schedules .<q>on a gaap basis , our earnings per fully diluted share decreased to $ 2.03 compared to $ 2.07 last year .<q>for many of our competitors , this number is over 50 % .<q>we now expect full year operating expenses to be in the range of down 1 % to flat year - over - year in constant currency .<q>for the full year , at current rates , currency translation is expected to be about neutral to sales growth to positively impact operating expense growth by less than 1 percentage point and to negatively impact earnings per share by about 3 percentage points .<q>combined lc instrument platform sales and lc - ms instrument platform sales were flat and ta 's instrumentation system sales declined 10 % .<q>our future capital structure target of approximately 2.5 times net debt - to - ebitda remains unchanged , while our near - term focus is maintaining financial flexibility and variability in the macro environment .", "len_article": 40, "len_summary_gold": 4, "len_summary_pred": 16, "len_sent_scores": 40}